CCL announced as the only global laboratory partner for, first of its kind, fertility test

CCL CEO, Jonathan Shrewsbury

Cambridge Clinical Laboratories (CCL) has been announced as the sole global laboratory partner for the FSH receptor (FSH-R) polymorphism test by pMorph. This is the first and only UKAS-accredited UK test for pharmacogenomics in fertility (which satisfies the HFEA license requirements).

What does the FSHR Polymorphism test do?

The test looks at the sequence of DNA involved in recognising and responding to FSH (follicle stimulating hormone). This hormone is responsible for the recruitment and development of eggs within the ovaries. During IVF treatment the doctor prescribes drugs containing FSH to stimulate the ovaries to produce numerous eggs – these are required for embryo development. The FSH-R polymorphism test will indicate the sensitivity of receptors in the patient’s ovaries and provide vital information on how the patient may respond to IVF treatment. This result will help clinicians decide on the right dose and type of stimulation, thus improving the chances of IVF success.

 

Why is testing for a polymorphism in the FSH receptors important in fertility?
This simple PCR-based blood test can provide genetic information to the doctor that cannot be gained in any other way. This additional information will help with tailoring the stimulation treatment for each patient and will maximise the chances of gaining eggs for IVF. By achieving a good number of eggs we are increasing the chance of a successful IVF outcome, which benefits both patients and clinicians. IVF treatment is a significant physical   emotional and financial commitment and any tools we have available to help manage expectations and tailor treatment is important. The FSH-R polymorphism test is an example of personalised medicine – the right treatment first time for every patient.

CCL CEO, Jonathan Shrewsbury, says: “At CCL we look to offer the most innovative, state of the art personalised medicine tests to the UK market, and abroad. Our work enables healthcare professionals to provide the most effective clinical outcomes for their patients. The FSHR Polymorphism fertility test, by pMorph Genetic Testing,is our first step into supporting development in the fertility field. We’re incredibly excited to support this being made available to a global market.

Jonathan adds: “We are living in revolutionary times with regards to personalised healthcare diagnostics and specifically targeted therapeutics, and we plan for CCL to be at the forefront of that revolution.”

To find out more about this test visit https://www.camclinlabs.co.uk/fertilityand www.pmorph.com